Allergan Botox User Fee For Hyperhidrosis Indication Is May 23
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan’s pending sBLA for use of Botox in the treatment of primary axillary hyperhidrosis has a user fee goal of May 23.